Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)
China flag China · Delayed Price · Currency is CNY
24.22
-0.72 (-2.89%)
May 20, 2026, 11:29 AM CST

SHA:600993 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
3,8593,8163,6803,0983,4973,363
Other Revenue
50.4650.4648.538.335.1222.53
3,9103,8673,7283,1373,5323,385
Revenue Growth (YoY)
4.48%3.72%18.85%-11.20%4.35%21.26%
Cost of Revenue
2,0051,9661,9971,8292,0382,019
Gross Profit
1,9051,9011,7311,3071,4941,366
Selling, General & Admin
1,1441,1471,051825.21886.06818.05
Research & Development
76.3478.1166.6969.0177.8966.73
Other Operating Expenses
28.3225.3517.624.3926.1625.06
Operating Expenses
1,2471,2561,144922.541,000912.9
Operating Income
657.76644.71587.12384.73494.16453.38
Interest Expense
-7.21-7.38-7.38-16.85-11.69-10.21
Interest & Investment Income
67.7570.0578.88151.598.9278.85
Currency Exchange Gain (Loss)
0.130.13-0.060.050.04-0.21
Other Non Operating Income (Expenses)
2.012.160.99-3.78-6.22-4.92
EBT Excluding Unusual Items
720.45709.68659.55515.65575.22516.89
Impairment of Goodwill
-2.28-2.28----
Gain (Loss) on Sale of Investments
-5.46-5.77-6.57-0.35-38.0617.63
Gain (Loss) on Sale of Assets
-5.23-5.21-0.141.12-0.01-0.5
Asset Writedown
-1.92-0.01-5.25--0.34-0.44
Other Unusual Items
12.2512.599.968.2822.3314.58
Pretax Income
717.82709657.55524.7559.14548.16
Income Tax Expense
102.84103.29109.2672.8679.7874.11
Earnings From Continuing Operations
614.98605.71548.3451.84479.35474.05
Minority Interest in Earnings
-24.48-24.22-20.2-8.59-0.78-9.46
Net Income
590.51581.49528.09443.25478.57464.59
Net Income to Common
590.51581.49528.09443.25478.57464.59
Net Income Growth
10.58%10.11%19.14%-7.38%3.01%10.87%
Shares Outstanding (Basic)
431431429430431430
Shares Outstanding (Diluted)
431431429430431430
Shares Change (YoY)
0.17%0.32%-0.23%-0.19%0.22%-0.43%
EPS (Basic)
1.371.351.231.031.111.08
EPS (Diluted)
1.371.351.231.031.111.08
EPS Growth
10.40%9.76%19.42%-7.21%2.78%11.34%
Free Cash Flow
596.17481.07293.76355.7266.84532.07
Free Cash Flow Per Share
1.381.120.680.830.621.24
Dividend Per Share
0.7000.7000.6200.4000.3500.350
Dividend Growth
12.90%12.90%55.00%14.29%-16.67%
Gross Margin
48.73%49.16%46.43%41.68%42.30%40.36%
Operating Margin
16.82%16.67%15.75%12.26%13.99%13.39%
Profit Margin
15.10%15.04%14.17%14.13%13.55%13.73%
Free Cash Flow Margin
15.25%12.44%7.88%11.34%7.55%15.72%
EBITDA
718.34703.43638.41434.2541.14495.12
EBITDA Margin
18.37%18.19%17.13%13.84%15.32%14.63%
D&A For EBITDA
60.5858.7251.2949.4846.9841.74
EBIT
657.76644.71587.12384.73494.16453.38
EBIT Margin
16.82%16.67%15.75%12.26%13.99%13.39%
Effective Tax Rate
14.33%14.57%16.61%13.89%14.27%13.52%
Revenue as Reported
3,9103,8673,7283,1373,5323,385
Advertising Expenses
-222.35161.6472.5681.2559.99
Source: S&P Global Market Intelligence. Standard template. Financial Sources.